IMMP Immutep

Immutep to Participate in Upcoming Investor Conferences

Immutep to Participate in Upcoming Investor Conferences

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --   (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:

  
Jones Healthcare and Technology Innovation Conference 
Location:Las Vegas, NV 
Date:        Wednesday, 9 April 2025 
Time:4:30 pm ET 
   
The Citizens Life Sciences Conference
Location:New York, NY
Date:Thursday, 8 May 2025
Time:1:00 pm ET
 
Jefferies Global Healthcare Conference
Location: New York, NY
Date:Wednesday & Thursday, 4 & 5 June 2025
  

Additional information for the Jefferies presentation will be made available closer to the conference on the  within the Investors & Media section of Immutep’s website.

About Immutep

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit .

Australian Investors/Media:

Catherine Strong, Sodali & Co.

+61 (0)406 759 268;

U.S. Media:

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000;



EN
02/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immutep

 PRESS RELEASE

Immutep Quarterly Activities Report Q3 FY25

Immutep Quarterly Activities Report Q3 FY25 Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025Patient enrolment completed for the EFTISARC-NEO Phase II trial evaluating efti with radiotherapy and KEYTRUDA® in resectable soft tissue sarcomaPatient enrolment completed for the INSIGHT-003 Phase I trial evaluating efti with KEYTRUDA® and chemotherapy as first-line treatment of advanced or metastatic 1L NSCLCStrong cash position of A$146.25 mil...

 PRESS RELEASE

Immutep to Participate in Upcoming Investor Conferences

Immutep to Participate in Upcoming Investor Conferences SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --   (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:   Jones Healthcare and Technology Innovation Conference Location:Las Vegas, NV Date:        Wednesday, 9 April 2025 Time:4:30 pm ET    The Citizens Life Sciences ConferenceLocation:New York, NYDate:Thursday, 8 May 2025Time:1:00 ...

 PRESS RELEASE

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Li...

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol approximately 756 patients at more than 150 clinical sitesTrial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology  SYDNEY, AUSTRALIA, March 25, 2025 (GLOBE NEWSWIRE) --   (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunothera...

 PRESS RELEASE

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the E...

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025 SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) --   (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025. The Trial in Progress poster includes an overview and study design of the TACT...

 PRESS RELEASE

Immutep Quarterly Activities Report Q2 FY25

Immutep Quarterly Activities Report Q2 FY25 Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival (OS) and 81.0% 24-month OS rate, significantly outperforming historical controlsPromising new results in first line head & neck cancer with PD-L1 CPS

ResearchPool Subscriptions

Get the most out of your insights

Get in touch